ERBB2 and cancer: c-Src inhibitor-1 efficacy in overcoming resistance to EGFR inhibitors was also reported in HER2+ gastric and biliary tract tumors: cancer cells resistant to the anti-HER2 antibody trastuzumab showed higher c-Src and FAK phosphorylation levels, compared to sensitive cells.